Determination of interaction parameters for reversibly self-associating antibodies: A comparative analysis

Mandi Hopkins¹, Cherie Lambert¹, Arun Parupudi², Jared Bee², and David Bain¹

¹Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus

²Analytical Sciences Department, MedImmune, LLC



Discovery. Development. Delivery.

Purpose

- Long-term: Gain a more predictive and mechanistic understanding of reversible self-association (RSA) in therapeutic proteins
- <u>Immediate</u>: Define stoichiometric assembly pathways, interaction affinities, and nonideality terms
- Key points:
 - » RSA and nonideality mask one another at sufficiently high concentrations
 - » Globally fit concentration-dependent data sets with direct boundary fitting
 - » This approach allows for determination of molecular parameters

Sedimentation Velocity (SV) AUC



mAb A one concentration (1 mg/mL) c(s) analysis

Schuck P (2000) *Biophys J* 78: 1606-1619

Sedimentation Velocity (SV) AUC



Skaggs School of Pharmacy and Pharmaceutical Sciences

mAb A one concentration (1 mg/mL) $g(s^*)$ analysis

Philo JS (2006) Anal Biochem 354: 238-246

Sedimentation Velocity (SV) AUC



Skaggs School of Pharmacy and Pharmaceutical Sciences

mAb A concentration-dependent g(s) analysis

g(s*) plots reveal nonideality and RSA



Skaggs School of Pharmacy and Pharmaceutical Sciences

$g(s^*)$ plots reveal nonideality and RSA



Skaggs School of Pharmacy and Pharmaceutical Sciences

g(s*) plots reveal nonideality and RSA



Skaggs School of Pharmacy and Pharmaceutical Sciences

Direct fitting with SEDANAL

- Allows global fitting of multispecies and multicomponent systems
- Curve-fitting algorithm using nonlinear least-squares (NLLS) analysis
- Resolution of interaction rate constants (k_{off}, k_{on}), equilibrium constants (K_{eq}, K_d), hydrodynamic (k_s) and thermodynamic (BM₁) nonideality by direct fitting of data
 - » $s_{20,w}$, MW, % irreversible species, initial loading concentrations, fringe offset

Direct fitting with SEDANAL

Control file 54\User_data\nonideal mono-di-irr di.abd	Browse	New B	Compute Star	e ndard deviati	on	Right-click on to have it he	a parameter Id constant		2	Store control file and start fit
Model to be fitted mono-di-inc. di	▼ Madalathar	Last 👻	C Sun	n of absolute	deviations	Fit	itting Constant			Store control file only
Number of points between meniscus and base of cell	Analyze data Simulate data	parar	nirt-click on a neter to set li	mits Indef	ïnite self-ass'r	n Use Molec	e deleted points sular parameters	Output files	Package	Cancel
Kinetic parameters Keq kf	kr	Molari	mass (g/mole	e) 147	A 22	A2 94000 294				
ZA = AZ [610		Densit Mass e	y increment	0.27 0.27	7173 0. 393 3	27173 0.2	7173			
	•	Hydr. o	LL CELLS conc. dep., K		0536442 0.	00536442 0.00	0536442			
			•							Þ
	y									
Cell data file Browse Data (right-click for cell menu)	Description, cell data	Meniscus, cm	Fit from radius	Fit to radius, cm	Base of cell, cm	Loading conc of A, g/L	Loading conc Wratio A'/A			_
1 20170608_0.3mg.abr	A 0.3mgml	5.85914	6.35	7.12	7.2	0.325066	0.0259648	K		-
2 20170608_0.5mg.abr	A 0.5mgml	5.903	6.35	7.12	7.2	0.536676	0.0259648			
3 20170608_1mg.abr 💌	A 1mgml	5.88763	6.3	7.12	7.2	1.11851	0.0259648			
4 20170608_3mg.abr	A 3mgml	6.00618	6.42	7.11	7.2	3.21613	0.0259648			
5 20170608_5mg.abr 💌	A 5mgml	5.91793	6.4	7.12	7.2	5.56031	0.0259648			
6 20170608_10mg.abr 💌	A 10mgml	5.98481	6.4	7.11	7.2	11.1348	0.0259648			
7							0.0259648			
8							0.0259648			
9							0.0259648			
10							0.0259648			•
						4			Þ	

SEDANAL fits timedifference curves to remove systematic error



Skaggs School of Pharmacy and Pharmaceutical Sciences

Stafford and Sherwood (2004) Biophys Chem 108:231-243

RESULTS SEDANAL global fitting of concentrationdependent time difference curves



Non-interacting example: mAb A

Monomer (A) with irreversible dimer (A') and nonideality RMSD = 8.84E-03 fringes

Resolved parameters:

s_{20,w}: 6.47 k_s: 5.22 mL/g BM₁: 0.20 mL/g A': 2 %

MW: A & A'

s_{20,w}: A'

Fixed or constrained:



Skaggs School of Pharmacy and Pharmaceutical Sciences

Interacting example: mAb C

Monomer (A) – trimer (A3) – hexamer (A6) 1-3-6

RMSD = 5.19E-02

Reaction 1: 3A = A3Reaction 2: 2A3 = A6



Skaggs School of Pharmacy and Pharmaceutical Sciences

Interacting example: mAb C

Model	RMSD	F _{calculated}
1-3	6.51E-02	16.350
1-2-3	3.42E-02	4.512
1-2-4	2.83E-02	3.090
1-2-4-6	2.74E-02	2.896
1-3-6	5.19E-02	10.392
isodesmic	1.61E-02	1.000
		1000

$$F_{calculated} = \frac{RMSD_1^2}{RMSD_2^2} \qquad F_{critical} = 1.002$$

G,





Interacting example: mAb C

Isodesmic with nonideality RMSD = 1.61E-02 fringes

Resolved parameters:

K_d: 32.8 μM s_{20,w}: 6.51 k_s: 35.4 mL/g BM₁: 8.10 mL/g



1.4

1.2-

1.0

∨ Fringes
0.6
0.4

0.2

0.0 -0.2

2.0-1.8-

1.6

1.4 1.2 1.0 0.8

0.6

6.2

1.1-

0.9

0.5

6.4

Fringes 0.7

 \triangleleft 0.3 6.4

6.6

Radius (cm)

6.8

7.0

Fringes

6.2

Hopkins MM, et al (2018) J Pharm Sci In Press

6.4

6.6

Radius (cm)

6.8

7.0

1.0

0.6 0.2 -0.2

Comparison of simulated and experimental $g(s^*)$ plots



Skaggs School of Pharmacy and Pharmaceutical Sciences

DISCUSSION

Summary & Conclusions

- Direct boundary fitting of SV data allows for determination of stoichiometric binding models, interaction affinities, and nonideality terms, allowing for the deconvolution of RSA from nonideality
- Observed distinct kinetics, equilibrium constants ranging from microto millimolar, and stoichiometric models from monomer-dimer to isodesmic
- Investigating the accuracy and precision of nonideality terms, possibly due in part to cross-correlation

DISCUSSION

Future Directions

- Qualitative preliminary studies reveal strong temperature dependence, as well as sensitivity to pH and salt concentration
- Future studies will quantitatively address these findings in more detail using thermodynamic linkage analysis

Acknowledgements & Support

- Dr. David Bain, University of Colorado Anschutz Medical Campus
- Dr. Walter Stafford, Harvard Medical School
- Dr. Jack Correia, University of Mississippi Medical Center



A member of the AstraZeneca Group